Showing results (1-10 of 139) with videos related to
Sort By:
Pageof 14
Immunity|October 9, 2024
TIL the end: Tracking T cell clonotype dynamics during adoptive cell therapyAnthony C Buzzai, Thomas TütingFrontiers in Immunology|July 13, 2026
Oncolytic virotherapy counteracts the selection of IFN-unresponsive cancer cells post-immunotherapy but is limited by the emergence of dedifferentiated cancer cellsSusan Gellert, Bastian Kruse, Johannes Peters, et al.Pigment Cell & Melanoma Research|April 27, 2013
T cell immunotherapy for melanoma from bedside to bench to barn and back: how conceptual advances in experimental mouse models can be translated into clinical benefit for patientsThomas TütingExperimental Dermatology|April 18, 2007
Identification of type I interferon-associated inflammation in the pathogenesis of cutaneous lupus erythematosus opens up options for novel therapeutic approachesJoerg Wenzel, Thomas TütingMethods in Molecular Biology (Clifton, N.J.)|October 30, 2012
Biolistic DNA vaccination against melanomaJulia Steitz, Thomas TütingTrends in Immunology|May 7, 2016
Inflammation-Induced Plasticity in Melanoma Therapy and MetastasisMichael Hölzel, Thomas TütingThe Journal of Investigative Dermatology|April 18, 2008
An IFN-associated cytotoxic cellular immune response against viral, self-, or tumor antigens is a common pathogenetic feature in "interface dermatitis"Joerg Wenzel, Thomas TütingImmunity|February 21, 2019
Live or Let Die: T Cell Survival in Cancer ImmunotherapyJanne Ruotsalainen, Thomas TütingDermatologie (Heidelberg, Germany)|November 9, 2022
[Immunological mechanisms of cognitive dysfunction under systemic therapy in metastatic melanoma]Miriam Mengoni, Thomas Tüting, Evelyn GaffalHandbook of Experimental Pharmacology|December 12, 2007
Toll-like receptor-agonists in the treatment of skin cancer: history, current developments and future prospectsJoerg Wenzel, Damia Tormo, Thomas TütingPageof 14